EpiSwitch™ Featured in Presentations on Development and Validation of Blood-Based Predictive Biomarkers in Immune Checkpoint Inhibitor Programs

Data from study of EpiSwitch™ Suggest Independent Predictive Power of the 3D Genome Architecture Technology Platform in Immuno-Oncology - presented at Society for Immunotherapy of Cancer (SITC) Annual Meeting, co-authored by scientists from Merck KGaA, Darmstadt, Germany, Pfizer and Mayo Clinic

https://www.londonstockexchange.com/exchange/news/market-news/market-news-detail/OBD/14299993.html